KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Sales: 2009-2025

Historic Return on Sales for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to 0.48%.

  • Halozyme Therapeutics' Return on Sales rose 6.00% to 0.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48%, marking a year-over-year increase of 6.00%. This contributed to the annual value of 0.44% for FY2024, which is 10.00% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Return on Sales stood at 0.48% for Q3 2025, which was up 1.34% from 0.47% recorded in Q2 2025.
  • Halozyme Therapeutics' Return on Sales' 5-year high stood at 0.92% during Q1 2022, with a 5-year trough of 0.26% in Q1 2023.
  • In the last 3 years, Halozyme Therapeutics' Return on Sales had a median value of 0.39% in 2024 and averaged 0.38%.
  • Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 98bps in 2021, then plummeted by 66bps in 2023.
  • Halozyme Therapeutics' Return on Sales (Quarterly) stood at 0.91% in 2021, then slumped by 60bps to 0.31% in 2022, then rose by 3bps to 0.34% in 2023, then increased by 10bps to 0.44% in 2024, then grew by 6bps to 0.48% in 2025.
  • Its last three reported values are 0.48% in Q3 2025, 0.47% for Q2 2025, and 0.45% during Q1 2025.